Assessing DCog Short for Neurotoxicity in CAR-T

ConditionsNeurotoxicity Neurotoxicity Syndromes Hematologic Malignancy Immune Effector Cell Associated Neurotoxicity Syndrome

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorBeth Israel Deaconess Medical Center

About this trial

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Eligibility criteria

Qualifiers

participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.

Visual acuity of 20/100 or better.

Disqualifiers

patients < 18 years old

pregnant women

prisoners

adults unable to consent,

Trial design

Treatments tested in this trial

DCog Short

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

Beth Israel Deaconess Medical Center02215, BostonMassachusetts, United States

Sponsors and collaborators

Beth Israel Deaconess Medical Center

Lead sponsor

Source ClinicalTrials.gov